Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Famitinib - Jiangsu Hengrui Medicine

Drug Profile

Famitinib - Jiangsu Hengrui Medicine

Alternative Names: Famitinib maleate; SHR 1020

Latest Information Update: 02 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Fudan University; Jiangsu Hengrui Medicine Co.
  • Class Antineoplastics; Diethylamines; Fluorobenzenes; Indoles; Pyrroles; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists; Vascular endothelial growth factor receptor-3 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Cervical cancer
  • Phase III Colorectal cancer; Gastrointestinal stromal tumours; Non-small cell lung cancer
  • Phase II Biliary cancer; Endometrial cancer; Fallopian tube cancer; HER2 negative breast cancer; Nasopharyngeal cancer; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours; Thyroid cancer; Triple negative breast cancer; Urogenital cancer
  • Phase I/II Osteosarcoma
  • Clinical Phase Unknown Fibroma
  • No development reported Breast cancer

Most Recent Events

  • 30 Mar 2024 Second Affiliated Hospital of Xi'an Jiaotong University plans phase-II trial for Non small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in March 2024 (PO), (NCT06336954)
  • 09 Feb 2024 Jiangsu HengRui Medicine terminates phase III trial in Gastrointestinal stromal tumours (Inoperable/Unresectable, Late-stage disease) in China (PO) due to R&D business strategy (NCT04409223)
  • 01 Feb 2024 Jiangsu Province Nanjing Brain Hospital initiates a phase II trial in Non-small cell lung cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in China (PO) (NCT06332300)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top